Globestar Therapeutics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Globestar Therapeutics (GSTC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Globestar Therapeutics vs Its Competitors
- Scale: Globestar Therapeutics ranks #485 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Globestar Therapeutics's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Globestar Therapeutics Corporation | - | - | - | Yes |
| Competitors combined (58) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GSTC Stock Performance relative to its Competitors
GSTC Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Arcus Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Globestar Therapeutics's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Globestar Therapeutics Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Globestar Therapeutics Corporation | 0.12 | - |
| Pfizer Inc | 160,255.88 | 63,696.00 |
| Bristol myers Squibb Company | 125,870.08 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 77,889.86 | 15,534.70 |
| Moderna Inc | 75,198.12 | 2,228.00 |
| Biontech Se | 23,408.64 | 3,243.68 |
| SUBTOTAL | 509,627.75 | 137,222.09 |
Sign in to see all competitors of Globestar Therapeutics Corporation.
Sources: Globestar Therapeutics Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Globestar Therapeutics Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Globestar Therapeutics's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Emergent Biosolutions Inc | MCM Products 65.21 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Globestar Therapeutics Corporation.
Globestar Therapeutics's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Globestar Therapeutics Corporation | 0 | - | - |
| Pfizer Inc | 160,256 | 849,280 | 58,267 |
| Bristol myers Squibb Company | 125,870 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 77,890 | 1,008,092 | 280,902 |
| Moderna Inc | 75,198 | 474,043 | -670,426 |
| Biontech Se | 23,409 | 415,483 | -164,532 |
| PEERS TOTAL | 509,628 | 959,984 | 64,165 |
Sign in to see all peers for Globestar Therapeutics Corporation.
Globestar Therapeutics's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | US 54.29 % |
| Compugen Ltd | GB 89.33 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Globestar Therapeutics Corporation.
Globestar Therapeutics's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Globestar Therapeutics's industry classification, broader than the peer set above. Market cap in millions of $.Globestar Therapeutics ranks #485 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 816, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,029,931 | 19.10 % |
| 2 | Johnson and Johnson | 643,198 | 11.93 % |
| 3 | Beone Medicines Ltd | 553,175 | 10.26 % |
| 4 | Abbvie Inc | 461,540 | 8.56 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 485 | Globestar Therapeutics Corporation | 0 | 0.00 % |
Market cap and industry share for the rest of Globestar Therapeutics's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Globestar Therapeutics's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 480 | Jaguar Health Inc | 0 | -94.75 % |
| 481 | Psyence Biomedical ltd | 0 | -95.50 % |
| 482 | Petros Pharmaceuticals inc | 0 | -83.33 % |
| 483 | Ovid Therapeutics Inc | 0 | 92.69 % |
| 484 | Prophase Labs Inc | 1,234 | 12.3% |
| 485 | Globestar Therapeutics Corporation | 0 | - |
| 486 | Clearmind Medicine Inc | 1,234 | 12.3% |
| 487 | Protokinetix Incorporated | 1,234 | 12.3% |
| 488 | Regen Biopharma Inc | 1,234 | 12.3% |
| 489 | Vincerx Pharma Inc | 1,234 | 12.3% |
| 490 | Kala Bio inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Globestar Therapeutics's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-01. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Globestar Therapeutics's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | - | 21.75 % | 24.27 % | 18.53 % | - |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Globestar Therapeutics's BCG Growth-Share Matrix
Relative market share (vs Globestar Therapeutics's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Globestar Therapeutics falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Globestar Therapeutics's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 816 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Globestar Therapeutics's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Globestar Therapeutics's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Globestar Therapeutics's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Globestar Therapeutics falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Globestar Therapeutics's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 52.7 points above the industry aggregate.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (51.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-11.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Globestar Therapeutics's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Globestar Therapeutics Corporation | 0.00 | 0.01 | - |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Biontech Se | 3.58 | 7.54 | - |
Sign in to see all peers for Globestar Therapeutics Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Globestar Therapeutics's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Globestar Therapeutics Corporation | Q2 2024 | - | - |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Biontech Se | Q4 2025 | +9.0 % | - |
| PEERS TOTAL | +6.8 % | -72.3 % |
Sign in to see all peers for Globestar Therapeutics Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Globestar Therapeutics's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Globestar Therapeutics Corporation | Q2 2024 | - | - |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Biontech Se | Q4 2025 | +23.9 % | -36.1 % |
Sign in to see all peers for Globestar Therapeutics Corporation.
Globestar Therapeutics's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Globestar Therapeutics Corporation | - | - | - |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Moderna Inc | - | - | - |
| Biontech Se | - | - | - |
Sign in to see all peers for Globestar Therapeutics Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Globestar Therapeutics's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Globestar Therapeutics Corporation | - | - |
| Pfizer Inc | 36.87 | 2.52 |
| Bristol myers Squibb Company | 13.53 | 2.56 |
| Regeneron Pharmaceuticals Inc | 18.20 | 5.01 |
| Moderna Inc | - | 33.75 |
| Biontech Se | - | 7.22 |
| PEERS AVERAGE | 55.57 | 3.71 |
Sign in to see all peers for Globestar Therapeutics Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.